GD
VRTX icon

Grandfield & Dodd’s Vertex Pharmaceuticals VRTX Stock Holding History

Grandfield & Dodd’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.69M Buy
21,704
+473
+2% +$221K 0.55% 49
2025
Q4 		$9.63M Buy
21,231
+1,411
+7% +$608K 0.55% 50
2025
Q3 		$7.76M Buy
19,820
+1,533
+8% +$641K 0.44% 52
2025
Q2 		$8.14M Buy
18,287
+141
+0.8% +$65K 0.48% 48
2025
Q1 		$8.8M Buy
18,146
+1,182
+7% +$551K 0.55% 49
2024
Q4 		$6.83M Buy
16,964
+2,820
+20% +$1.31M 0.42% 53
2024
Q3 		$6.58M Buy
14,144
+2,538
+22% +$1.22M 0.39% 54
2024
Q2 		$5.44M Buy
11,606
+2,491
+27% +$1.08M 0.34% 55
2024
Q1 		$3.81M Buy
9,115
+129
+1% +$54.5K 0.24% 62
2023
Q4 		$3.66M Buy
8,986
+75
+0.8% +$27.7K 0.25% 60
2023
Q3 		$3.1M Sell
8,911
-107
-1% -$37.4K 0.23% 65
2023
Q2 		$3.17M Buy
9,018
+30
+0.3% +$10.1K 0.22% 65
2023
Q1 		$2.83M Buy
8,988
+151
+2% +$45.3K 0.2% 73
2022
Q4 		$2.55M Buy
8,837
+234
+3% +$71.3K 0.19% 71
2022
Q3 		$2.49M Hold
8,603
– – 0.2% 70
2022
Q2 		$2.42M Buy
8,603
+13
+0.2% +$3.48K 0.19% 74
2022
Q1 		$2.24M Buy
8,590
+150
+2% +$35.6K 0.15% 75
2021
Q4 		$1.85M Buy
8,440
+519
+7% +$101K 0.12% 84
2021
Q3 		$1.44M Sell
7,921
-11
-0.1% -$2.15K 0.1% 86
2021
Q2 		$1.6M Buy
7,932
+70
+0.9% +$14.6K 0.11% 83
2021
Q1 		$1.69M Buy
7,862
+19
+0.2% +$4.17K 0.13% 80
2020
Q4 		$1.85M Buy
7,843
+221
+3% +$50.7K 0.15% 76
2020
Q3 		$2.07M Buy
7,622
+38
+0.5% +$10.5K 0.19% 73
2020
Q2 		$2.2M Buy
7,584
+145
+2% +$39.3K 0.21% 70
2020
Q1 		$1.77M Buy
7,439
+147
+2% +$33.7K 0.21% 70
2019
Q4 		$1.6M Buy
7,292
+285
+4% +$57.7K 0.15% 78
2019
Q3 		$1.19M Buy
7,007
+415
+6% +$73.4K 0.12% 83
2019
Q2 		$1.21M Buy
6,592
+312
+5% +$54.5K 0.12% 82
2019
Q1 		$1.16M Buy
6,280
+41
+0.7% +$7.57K 0.12% 84
2018
Q4 		$1.03M Buy
6,239
+61
+1% +$10.6K 0.12% 84
2018
Q3 		$1.19M Buy
6,178
+45
+0.7% +$8.01K 0.12% 85
2018
Q2 		$1.04M Buy
6,133
+15
+0.2% +$2.33K 0.11% 93
2018
Q1 		$997K Sell
6,118
-130
-2% -$21.2K 0.11% 93
2017
Q4 		$936K Buy
6,248
+103
+2% +$15.3K 0.1% 100
2017
Q3 		$934K Buy
6,145
+340
+6% +$51.2K 0.1% 97
2017
Q2 		$748K Buy
5,805
+90
+2% +$10.8K 0.09% 107
2017
Q1 		$625K Buy
5,715
+70
+1% +$6.16K 0.08% 111
2016
Q4 		$416K Buy
5,645
+500
+10% +$40.7K 0.05% 134
2016
Q3 		$449K Buy
5,145
+305
+6% +$28.8K 0.06% 127
2016
Q2 		$416K Buy
4,840
+194
+4% +$16.8K 0.06% 122
2016
Q1 		$369K Buy
4,646
+1,520
+49% +$137K 0.05% 129
2015
Q4 		$393K Buy
3,126
+505
+19% +$61K 0.06% 123
2015
Q3 		$273K Sell
2,621
-100
-4% -$12.8K 0.05% 145
2015
Q2 		$336K Sell
2,721
-86
-3% -$10.8K 0.05% 136
2015
Q1 		$331K Hold
2,807
– – 0.05% 131
2014
Q4 		$333K Hold
2,807
– – 0.05% 134
2014
Q3 		$315K Buy
2,807
+60
+2% +$5.71K 0.05% 131
2014
Q2 		$260K Buy
+2,747
New +$193K 0.04% 159

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Grandfield & Dodd's VRTX Position: Q1 2026 in Review

Grandfield & Dodd increased its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, buying an estimated $221K and bringing the position to 21,704 shares worth $9.69M. The position accounts for 0.55% of the portfolio, ranked #49.

Grandfield & Dodd first reported a position in VRTX in Q2 2014 and has held it in 48 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Grandfield & Dodd held 21,704 shares of Vertex Pharmaceuticals worth $9.69M as of Q1 2026.
  • Grandfield & Dodd bought 473 Vertex Pharmaceuticals shares in Q1 2026, an estimated $221K.
  • Vertex Pharmaceuticals made up 0.55% of Grandfield & Dodd's portfolio in Q1 2026, its #49 holding.
  • Grandfield & Dodd first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.